Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans

2006 ◽  
Vol 24 (4) ◽  
pp. 711-721 ◽  
Author(s):  
Nobuyuki Shirai ◽  
Takahiko Naruko ◽  
Masahiko Ohsawa ◽  
Yoshihiro Ikura ◽  
Yoshimi Sugama ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Endothelin Receptors ◽  
Converting Enzyme ◽  
Endothelin 1 ◽  
Percutaneous Coronary ◽  
Endothelin Converting Enzyme

Expression and Localization of Renal Endothelin-1, Endotehlin Receptors and Endothelin Converting Enzyme in Human Renal Biopsy with Rejection after Kidney Transplantation

2000 ◽  
Vol 6 (S2) ◽  
pp. 610-611
Author(s):  
M. Kinjo ◽  
J. Papadimitriou ◽  
C. Drachenberg ◽  
M. R. Weir ◽  
C. Wei
Keyword(s):  
Kidney Transplantation ◽  
Mesangial Cells ◽  
Collecting Duct ◽  
Enzyme Level ◽  
Tissue Level ◽  
Renal Tissue ◽  
Endothelin Receptors ◽  
Converting Enzyme ◽  
Endothelin 1 ◽  
Endothelin Converting Enzyme

Endothelin (ET-1) is a potent renal and systemic vasoconstrictor and sodium regulating peptide. Endothelin synthesis in the kidney have been reported in glomerulus endothelial, epithelial and mesangial cells as well as in inner medullary collecting duct. Factors stimulating the production of endothelin include shear stress, hypoxia, vasoactive agents and cytokines. Endothelin binding to ET-A receptor in vascular smooth muscle cells stimulates vasoconstriction.Renal graft rejection is a major problem after kidney transplantation with severe renal damage and renal vasoconstriction. We hypothesized that renal tissue level of endothelin-1, endothelin receptors and endothelin converting enzyme (ECE) may increase in renal tissue with rejection after kidney transplantation. Therefore, the current study was designed to determine the endothelin-1 and endothelin receptors (ET-A and ET-B) as well as endothelin converting enzyme level by immunohistochemical staining (IHCS) in human renal tissue with rejection after kidney transplantation.

scholarly journals Effect of angiotensin converting enzyme gene polymorphism on patients with in-stent restenosis after percutaneous coronary intervention

2022 ◽  
Vol 20 (2) ◽  
pp. 403-409
Author(s):  
Tarek A. Abdelaziz ◽  
Randa H. Mohamed ◽  
Gehan F. Balata ◽  
Omar Y. El-Azzazy
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Angiotensin Converting Enzyme ◽  
Coronary Intervention ◽  
Converting Enzyme ◽  
Positive Interaction ◽  
Ace Gene ◽  
Stent Restenosis ◽  
Spin Column ◽  
Percutaneous Coronary ◽  
In Stent Restenosis

Purpose: To evaluate the association between common single nucleotide polymorphisms (SNPs) in angiotensin converting enzyme (ACE) gene and the risk of in-stent restenosis (ISR) and/or the response to angiotensin converting enzyme inhibitor ACEI in individuals with stable coronary artery disease (CAD) after stent implantation. Methods: The total population of this study consisted of 200 Egyptian individuals divided into 2 groups - in-stent restenosis (ISR) and non ISR group). Genomic DNA was withdrawn from EDTA whole blood applying a spin column approach and ACE gene insertion/deletion (I/D) polymorphisms were determined by polymerase chain reaction (PCR). Results: Carriers of allele D of ACE gene were significantly more liable to ISR occurrence. However, carriers of allele I were significantly more liable to ISR occurrence after administration of ACEI. There is a negative interaction between DD genotype of ACE gene and ACEI administration on ISR after percutaneous coronary intervention (PCI). However, there is a positive interaction between II and ID genotype of ACE gene and ACEI administration on ISR after PCI with bare metal stents (BMS). Conclusion: It is beneficial to implement ACEI in therapeutic regimen in individuals with ID or II genotypes of ACE gene, especially with BMS implementation.

Sign in / Sign up

Export Citation Format

Share Document